Malaria Clinical Trial
Official title:
Comparison of Two Strategies for the Delivery of Intermittent Preventive Treatment in Children (IPTc) in an Area of Seasonal Malaria Transmission
Antimalarial chemoprophylaxis can reduce morbidity and mortality from malaria in children. However, this approach to malaria control has not been implemented widely because of concerns over its possible effect on the development of resistance and natural immunity. Intermittent preventive treatment (IPT) may be able to achieve some of the beneficial effects of chemoprophylaxis without its drawbacks. Recently, it has been shown that IPT given to Senegalese children under the age of five years on three occasions during the malaria transmission season reduced the incidence of clinical malaria by approximately 90%. However, it is uncertain how this intervention can be most effectively delivered. Therefore, 26 Maternal and Child Health (MCH) trekking clinics in Upper River Division, south of the River Gambia, each with an average catchment population of 400-500 children under 5 years of age, will be randomly allocated to receive IPT from the MCH trekking team or from a IPT dispenser (village health worker, traditional birth attendant or a community mother based in a primary health care village). Treatment with a single dose of sulfadoxine /pyrimethamine (SP) plus three doses of amodiaquine will be given to all study subjects at monthly intervals on three occasions during the months of September, October and November. The primary end points will be the incidence of clinical attacks of malaria detected by passive case detection, and cost-effectiveness of the delivery methods. Important secondary endpoints will be the coverage and the equity of coverage of IPT in preventing malaria morbidity.
3. OBJECTIVES
The objective of this trial is to study the effectiveness and cost-effectiveness of two
approaches to the administration of intermittent preventive treatment to Gambian children -
distribution by village volunteers or through EPI trekking teams.
5 STUDY DESIGN AND METHODOLOGY
The unit of randomization will be the catchment population of the monthly EPI trekking
clinics. There are 33 trekking clinics in total on the south bank of URD of which 27 are
rural. The rural trekking clinics will be selected for randomization. 26 rural clusters (two
will be merged to give an even number) will be stratified by health facility catchment area
(Gambissara, Basse, Fatoto). Constrained randomization will be used to ensure balance within
strata with regard to distribution of PHC key villages and population size.
The bednet coverage in URD is estimated to 65%. However, during the enumeration, details of
bed net usage by the community will be assessed. In collaboration with the malaria control
programme, we will facilitate the provision of bed nets to households without one. At the
beginning of the rainy season permethrin will be provided to all households with bednets.
5.1 Malaria card
After the enumeration has been completed, a database containing the list of eligible
children will be established. The database will be used to generate the list of
participating study children in each village. A record system using appropriate visual aids
will be devised that can be used by an IPTc dispenser. This will consist of a "malaria card"
held by the mother or guardian of each child and an IPT register held by IPTc dispenser or
staff of the DHT trekking team. On the malaria card held by the mother, the compound number
and study number will be written in Arabic and English, together with the child's name and
the name of his or her parents. The dosage of trial medication to be given will be indicated
on the malaria card and the register using coloured circles and semi-circles (full circle
for one tablet and semi-circle for half a tablet). The register held by the IPTc dispenser
or DHT staff will contain similar information to that on the malaria card.
When a child presents to a health facility for medication, the DHT staff or the IPTc
dispenser will examine the malaria card of the study subject. Medication will only be given
to study subjects after correct identification and after matching the information on the
malaria card held by the mother and that on the register held by the IPTc dispenser or the
DHT. It is envisaged that the DHT staff and IPTc dispenser taking part in the study will be
paid modest salary supplements for their contribution to the project. However, the details
of payment will be discussed with the EPI unit and Basse DHT.
5.2 Cross-section survey
In December, at the end of the malaria transmission season, a cross-sectional survey of
children less than 6yrs will be undertaken in all the 26 clusters. A questionnaire to
determine asset rating and wealth index will be completed. Information on demographic, bed
net usage, socio-economic status, health seeking behaviour and utilisation patterns profiles
will be collected, a clinical history will be obtained and a physical examination will be
performed, including abdominal palpation for splenomegaly and measurement of height, weight
and axillary body temperature.
5.3 Distribution of tablets
5.3.1 Distribution of tablets in the villages
Each key PHC village has a health post staffed by a community health nurse. There are 29 PHC
villages and the majority of these have a village health worker and a traditional birth
attendant. The three towns with basic health facilities (Basse, Fatoto and Gambisara) will
be excluded from the evaluation, and the trial will focus on other communities in the study
area. The trial medication will be administered by IPTc dispenser based in a PHC village.
The IPTc dispenser will distribute the trial medication at a central point (usually a health
post) on the first Wednesday of the month during September, October and November. Mothers
and carers will be asked to bring their children to the central point during the morning
when the IPTc dispenser will be available to distribute the drugs. When a child presents to
the central point for medication, the IPTc dispenser will identify the study subject using
the malaria card held by the mother and match the information on the malaria card with that
on her register. When she is satisfied that she has correctly identify the study subject and
that the information on the malaria card matches those on her register, the correct dosage
of the trial medication will be given to the study subject.
The first dose of treatment will be taken under direct supervision of the IPTc dispenser and
she will mark her register and the malaria card to show that the child has received the
tablets. The remaining two doses will be given to the mother or guardian of the child with
clear instructions on how to administer the drugs.
5.3.2 Distribution of tablets in the trekking clinics A member of the MCH trekking team
(designated as an IPTc officer) of each of the 3 basic health facilities (Basse, Fatoto and
Gambissara) will be identified by the EPI team and given responsibility for delivery of IPT
at the trekking clinics, which are allocated by randomization to deliver IPTc. Thus, each
EPI team will deliver IPTc in some of its trekking clinics but not in others.
The dates of each monthly treatment will be written in Arabic and English on the "malaria
cards". To ensure that children do not receive more doses of IPTc than they should,
different coloured "malaria cards" will be issued to children in villages where children
will receive their medication from IPTc dispenser and to those allocated to receive
medication from the MCH trekking clinic. IPTc dispensers and IPTc officers will be taught
how to give medication only to children who have the correct coloured cards.
At the end of the malaria transmission season, the total number of complete treatment doses
each child in the trial has taken will be recorded. Compliance will be checked on a rolling
basis throughout the study by assessing the number of correct doses of medication received.
In addition, urine samples will be collected from a random sample of 100 children each month
in the two-week period following administration of IPTc to test for the presence of SP in
the urine using Eggelte dipsticks.
5.4 Morbidity surveillance during the rainy season
Passive surveillance for malaria will be maintained throughout the transmission season.
5.5 Surveillance for severe malaria
Records will be kept of admission of study children to Basse and Fatoto Health Centres.
Physicians and nurses based at these facilities will be asked to look out for any child with
severe malaria, and any admission attributed to malaria will be carefully documented.
5.6 Surveillance for overall and cause specific mortality
Deaths will be investigated using postmortem questionnaire techniques and cause of death
established wherever possible.
5.7 Nested case control study
To estimate the effect of inequalities in wealth on malaria morbidity and its prevention by
intermittent treatment, -a nested case control approach will be used to determine
distribution of malaria morbidity in relation to two measures of socioeconomic status - a
wealth rating scale and an asset index.
5.8 Study of cost-effectiveness
A cost-effectiveness analysis will be undertaken from a societal perspective, meaning that
all costs and effects, no matter to whom they accrue, will be measured and valued.
5.8.1 Programme costs:
The costs of the two modes of delivering IPTc will be assessed using the bottom-up or
'ingredients' approach which involves the identification of all the resources required by
the two modes of delivery.
5.8.2 Resource savings:
The modes of delivery will be compared with respect to the resource savings resulting from
fewer children being treated for malaria related illnesses as a result of better IPTc
coverage.
5.8.3 Cost-effectiveness:
For both modes of delivery, two cost-effectiveness ratios will be calculated: (i) cost per
child who fully adheres to treatment; (ii) cost per case of malaria averted. In addition,
net cost-effectiveness ratios will be calculated by subtracting resources saved from the
total programme cost divided by the relevant outcome measure. The incidence of malaria and
the costs will be compared between the two delivery arms and the cost per additional case
averted calculated.
5.9 Equity
The impact of the different delivery strategies on alleviating (or exacerbating) three forms
of equity will be measured. Equity outcomes and the cost of each delivery mode will also be
compared using benefit-incidence analysis.
5.9.1 Equality of utilization or adherence:
To determine impact in terms of IPT coverage, levels of adherence will also be compared
across the two delivery strategies; a cross-section survey will be used.
5.9.2 Equality of access:
Here we are measuring whether households have the same opportunity to benefit from each mode
of delivery. This involves defining and measuring financial access, geographical access,
informational access and cultural/gender barriers to access. Approximately 25 compliers and
25 non-compliers from a sub-sample of 12 clusters will be interviewed about factors
influencing access to each delivery strategy.
5.9.3 Benefit-incidence-analysis:
Utilization and access data for rich and poor households will be compared with the cost of
providing the service. This will involve the use of benefit-incidence-analysis to analyze
the impact of government expenditure on poverty.
5.9.4 Cost-effectiveness data collection:
Health service costing data including capital costs, consumables, salaries etc. will be
collected by careful review of health facility records and through consultation with
administration staff. Costs to the community will be collected using an interviewer
administered questionnaire recently developed by a GMP PhD student.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Completed |
NCT02527005 -
A Comparative Study of Azithromycin and S-P as Prophylaxis in Pregnant HIV+ Patients
|
Phase 1 |